- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04474210
A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants
An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-56136379 in Adult Participants
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Orlando, Florida, Forente stater, 32809
- Orlando Clinical Research Center
-
-
Texas
-
San Antonio, Texas, Forente stater, 78215
- The Texas Liver Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Body mass index (BMI) (kilograms [kg]/height [m]^2) between 18.0 and 38.0 kilogram/meter^2 (kg/m2) (inclusive), and body weight not less than (<) 50 kg
Participants with normal renal function:
- Have normal renal function defined as estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter/minute computed with the online calculator on the CKD-EPI website by use of the Chronic Kidney Disease Epidemiology Collaboration creatinine clearance (CKD-EPIcr) result
- Must have stable renal function as defined as: (a) for participants with impaired renal function: <20 percent (%) change in serum creatinine concentrations between screening and Day -1; (b) for healthy participants: a change in serum creatinine concentration <0.2 milligram per deciliter (mg/dL) between screening and Day -1
Participants with renal impairment:
- Have an impaired renal function based on eGFR as(eGFR computed with the online calculator on the CKD-EPI website providing eGFR (in mL/min units) by use of the CKD-EPIcr result: (a) eGFR <90 to 60 mL/minute for participants in Group 3 (mild renal impairment cohort); (b) eGFR 30 to 59 mL/minute for participants in Group 4 (moderate renal impairment cohort); (c) eGFR <30 mL/minute but not yet on hemodialysis, for participants in Group 1 (severe renal impairment and/or kidney failure); (d) eGFR <15 mL/minute and on hemodialysis, for participants in Group 5 (kidney failure)
- Concomitant medications to treat underlying disease states or medical conditions related to renal impairment are allowed. Participants must be on a stable dose of medication and/or treatment regimen for at least 2 months (3 months for thyroid hormone replacement therapy [HRT]) before dosing as well as during the study
Exclusion Criteria:
- Individuals who take creatine supplements, have a non-standard muscle mass such as amputation, malnutrition, or muscle wasting; because these factors are not accounted for in the prediction equations for GFR chronic kidney disease epidemiology collaboration (CKD EPI)
Participants with normal renal function:
- Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or Day -1, as deemed appropriate by the investigator
- Clinically significant abnormal physical examination, vital signs, body temperature, or 12 lead ECG at screening or Day -1, as deemed appropriate by the investigator
Participants with renal impairment:
- Evidence of clinically apparent concurrent disease based upon complete clinical laboratory testing, full physical examination, or medical history, except for controlled hypertension and those problems directly associated with the primary diagnosis of renal impairment
- Any clinically significant laboratory abnormality except abnormalities that may be caused by renal impairment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Part A: Group 1
Participants with severe renal impairment and/or kidney failure (estimated glomerular filtration rate [eGFR] less than [<] 30 milliliter[mL]/minute but not yet on hemodialysis) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Aktiv komparator: Part A: Group 2
Healthy participants with normal renal function (eGFR greater than or equal to [>=] 90 mL/minute), will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Eksperimentell: Part B: Group 3 (Optional)
Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Eksperimentell: Part B: Group 4 (Optional)
Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Eksperimentell: Part B: Group 5 (Optional)
Participants with kidney failure (eGFR: <15 mL/minute and on hemodialysis; pharmacokinetic [PK] to be evaluated during non-dialysis days) will receive a single oral dose of JNJ-56136379.
|
Participants will receive JNJ-56136379 tablets orally.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum Observed Plasma Analyte Concentration (Cmax)
Tidsramme: Up to Day 29
|
Cmax is defined as the maximum observed plasma analyte concentration.
|
Up to Day 29
|
Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax)
Tidsramme: Up to Day 29
|
Tmax is defined as the actual sampling time to reach the maximum observed plasma analyte concentration.
|
Up to Day 29
|
Area Under the Analyte Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC [0-24])
Tidsramme: Up to 24 hours postdose
|
AUC (0-24) is defined as area under the analyte concentration-time curve (AUC) from time 0 to 24 hours postdose, calculated by linear-linear trapezoidal summation.
|
Up to 24 hours postdose
|
Area Under the Analyte Concentration-time Curve From Time Zero to 144 Hours Postdose (AUC [0-144])
Tidsramme: Up to 144 hours postdose
|
AUC (0-144) is defined as AUC from time 0 to 144 hours postdose, calculated by linear-linear trapezoidal summation.
|
Up to 144 hours postdose
|
Area Under the Analyte Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last])
Tidsramme: Up to Day 29
|
AUC (0-last) is defined as AUC from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.
|
Up to Day 29
|
Area Under the Analyte Concentration-time Curve From Time Zero to Infinity (AUC [0-infinity])
Tidsramme: Up to Day 29
|
AUC (0-infinity) is defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) is the last observed measurable (non-BQL) concentration; and lambda(z) is apparent terminal elimination rate constant.
|
Up to Day 29
|
Total Apparent Oral Clearance (CL/F)
Tidsramme: Up to Day 29
|
CL/F is defined as total apparent oral clearance, calculated as dose/AUC (0-infinity).
|
Up to Day 29
|
Apparent Volume of Distribution (Vd/F)
Tidsramme: Up to Day 29
|
Vd/F is defined as apparent volume of distribution, calculated as dose/[lambda (z)*AUC (0-infinity)].
|
Up to Day 29
|
Apparent Terminal Elimination Rate Constant (Lambda[z])
Tidsramme: Up to Day 29
|
Lambda(z) is defined as apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log-transformed concentration vs time curve.
|
Up to Day 29
|
Apparent Terminal Elimination Half-life (t1/2)
Tidsramme: Up to Day 29
|
t1/2 is defined as apparent terminal elimination half-life, calculated as 0.693/lambda(z).
|
Up to Day 29
|
Percentage of JNJ-56136379 Excreted in Urine (Ae,%Dose)
Tidsramme: Up to Day 7
|
Ae,%Dose is defined as cumulative urinary recovery represented as a percentage of dose, calculated as 100*(Aetotal/Dose).
|
Up to Day 7
|
Renal Clearance (CLr)
Tidsramme: Up to 144 hours postdose
|
CLr is defined as renal clearance, calculated as Ae(0-144h)/AUC(144h).
|
Up to 144 hours postdose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Antall deltakere med uønskede hendelser som et mål på sikkerhet og tolerabilitet
Tidsramme: Inntil 8 uker
|
En AE er enhver uheldig medisinsk hendelse som oppstår hos en deltaker som har administrert et undersøkelsesprodukt, og det indikerer ikke nødvendigvis bare hendelser med klar årsakssammenheng med det relevante undersøkelsesproduktet.
|
Inntil 8 uker
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR108802
- 56136379HPB1010 (Annen identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyreinsuffisiens
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Oregon Health and Science UniversityFullført
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark
-
Amai Charitable TrustUkjent
-
The Methodist Hospital Research InstituteUkjentAkutt (cellulær) renal allograft avvisningForente stater
-
Universitaire Ziekenhuizen KU LeuvenUkjent
-
Medical University of ViennaFullførtAcidose, Renal Tubular
-
Johns Hopkins UniversityFullførtKlinisk T1 nyremasseForente stater
Kliniske studier på JNJ-56136379
-
Janssen Research & Development, LLCFullført
-
Janssen Sciences Ireland UCFullførtHepatitt B, kroniskBelgia, Forente stater, Japan, Korea, Republikken, Frankrike, Hong Kong, Canada, Italia, Thailand, Tyskland, Malaysia, Spania, Den russiske føderasjonen, Tyrkia, Storbritannia, Polen, Brasil, Tsjekkia, Kina
-
Janssen Sciences Ireland UCFullførtSunn | Hepatitt, kroniskFrankrike, Taiwan, Spania, Belgia, Bulgaria, Malaysia, Romania, Tyskland, Georgia, Moldova, Republikken
-
Janssen Sciences Ireland UCFullførtHepatitt BForente stater, Korea, Republikken, Frankrike, Belgia, Italia, Taiwan, Storbritannia, Thailand, Malaysia, Kina, Spania, Canada, Tyskland, Japan, Den russiske føderasjonen, Tyrkia, Ukraina, Polen, Hong Kong
-
Janssen Sciences Ireland UCFullførtHepatitt B, kroniskBelgia, Storbritannia, Frankrike, Italia, Tyskland, Spania, Polen
-
Janssen Research & Development, LLCFullført
-
Janssen Sciences Ireland UCFullførtNedsatt leverfunksjonTyskland
-
Arrowhead PharmaceuticalsFullførtHepatitt BAustralia, Hong Kong, New Zealand
-
Janssen Research & Development, LLCFullførtHepatitt B, kroniskFrankrike, Taiwan, Canada, Forente stater, Tyskland, Spania, Japan, Den russiske føderasjonen, Tyrkia, Storbritannia
-
Ottawa Hospital Research InstituteUkjentMeibomian kjerteldysfunksjon | BlefarittCanada